Controlling the spread of vancomycin-resistant enterococci. Is active screening worthwhile?

Journal of Hospital Infection

Volumn 88, Issue 4, 2014, Pages 191-198

  Humphreys, H ^a  

^a ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

Author keywords

Colonization; Molecular methods; Risk groups; Screening; Selective media; Vancomycin resistant enterococci

Indexed keywords

BACTERIAL COLONIZATION; BACTERIUM DETECTION; COST CONTROL; COST EFFECTIVENESS ANALYSIS; HIGH RISK POPULATION; HUMAN; INFECTION CONTROL; INFECTION PREVENTION; INFECTION RISK; LABORATORY TEST; NONHUMAN; REVIEW; SCREENING TEST; VANCOMYCIN RESISTANT ENTEROCOCCUS; COMMUNITY-ACQUIRED INFECTIONS; COST BENEFIT ANALYSIS; CROSS INFECTION; DRUG EFFECTS; GENETICS; INTENSIVE CARE UNIT; MICROBIOLOGY; PREVALENCE; PROCEDURES; RISK FACTOR;

ANTIINFECTIVE AGENT;

ANTI-BACTERIAL AGENTS; COMMUNITY-ACQUIRED INFECTIONS; COST-BENEFIT ANALYSIS; CROSS INFECTION; HUMANS; INFECTION CONTROL; INTENSIVE CARE UNITS; PREVALENCE; RISK FACTORS; VANCOMYCIN-RESISTANT ENTEROCOCCI;

EID: 84920027025     PISSN: 01956701     EISSN: 15322939     Source Type: Journal    
DOI: 10.1016/j.jhin.2014.09.002     Document Type: Review

References (57)

1. Arias C.A., Murray B. The rise of the Enterococcus: beyond vancomycin resistance. Nat Rev Med 2012, 10:266-278.
2. Reik R., Tenover F.C., Klein E., McDonald C.L. The burden of vancomycin-resistant enterococcal infections in US hospitals, 2003 to 2004. Diagn Microbiol Infect Dis 2008, 62:81-85.
3. Deshpande L.M., Fritsche T.R., Moet G.J., Biedenbach D.J., Jones R.N. Antimicrobial resistance and molecular epidemiology of vancomycin-resistant enterococci from North America and Europe: a report from the SENTRY antimicrobial surveillance program. Diag Microbiol Infect Dis 2007, 58:163-170.
4. Sievert D.M., Ricks P., Edwards J.R., et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010. Infect Control Hosp Epidemiol 2013, 34:1-14.
5. European Centre for Disease Prevention and Control Surveillance Report Point prevalence survey of healthcare-associated infections and antimicrobial use in European hospitals, 2011-2012 July 2013, ECDC, Stockholm.
6. DiazGranados C.A., Zimmer S.M., Klein M., Jernigan J.A. Comparison of mortality associated with vancomycin-resistant and vancomycin-susceptible enterococcal bloodstream infections: a meta-analysis. Clin Infect Dis 2005, 41:327-333.
7. DiazGranados C.A., Jernigan J.A. Impact of vancomycin resistance on mortality among patients with neutropenia and enterococcal bloodstream infection. JInfect Dis 2005, 191:588-595.
8. Carmeli Y., Eliopoulos G., Mozaffari E., Samore M. Health and economic outcomes of vancomycin-resistant enterococci. Archs Intern Med 2002, 162:2223-2228.
9. Lloyd-Smith P., Younger J., Lloyd-Smith E., Green H., Leung V., Romney M.G. Economic analysis of vancomycin-resistant enterococci at a Canadian hospital: assessing attributable cost and length of stay. JHosp Infect 2013, 85:54-59.
10. US Department of Health and Human Services, Centers for Disease Control and Prevention Antibiotic resistance threats in the United States 2013, Available at:. http://www.cdc.gov/drugresistance/threat-report-2013/.
11. Muto C.A., Jernigan J.A., Ostrowsky B.E., et al. SHEA guideline for preventing nosocomial transmission of multi-drug resistant strains of Staphylococcus aureus and Enterococcus. Infect Control Hosp Epidemiol 2003, 24:362-386.
12. Cookson B.D., Macrae M.B., Barrett S.P., et al. Guidelines for the control of glycopeptide-resistant enterococci in hospitals. JHosp Infect 2006, 62:6-21.
13. Ofner-Agostina M., Varia M., Johnston L., et al. Infection control and antimicrobial restriction practices for antimicrobial-resistant organisms in Canadian tertiary care hospital. Am J Infect Control 2007, 35:563-568.
14. Tacconelli E., Cataldo M.A. Vancomycin-resistant (VRE): transmission and control. Int J Antimicrob Agents 2008, 31:99-106.
15. Armeanu E., Bonten M.J.M. Control of vancomycin-resistant enterococci. One size fits all?. Clin Infect Dis 2005, 41:210-216.
16. Cohen M.J., Adler A., Block C., et al. Acquisition of vancomycin-resistant enterococci in internal medicine wards. Am J Infect Control 2009, 37:111-116.
17. Pan S.-C., Wang J.-T., Chen Y.-C., Chang Y.-Y., Chen M.-L., Chang S.-C. Incidence of and risk factors for infection or colonisation of vancomycin-resistant enterococci in patients in the intensive care unit. Plos ONE 2012, 7:e47297.
18. Padiglione A.A., Wolfe R., Grabsch E.A., et al. Risk factors for new detection of vancomycin-resistant enterococci in acute-care hospitals that employ strict infection control procedures. Antimicrob Agents Chemother 2003, 47:2492-2498.
19. Datta R., Huang S.S. Risk of post discharge infection with vancomycin-resistant Enterococcus after initial infection or colonisation. Infect Control Hosp Epidemiol 2010, 31:1290-1293.
20. Weddle G., Jackson M.A., Selvarangan R. Utility of a focused vancomycin-resistant enterococci screening protocol to identify colonisation in hospitalised children. Am J Infect Control 2012, 40:891-892.
21. Drees M., Snydman D.R., Schmid C.H., et al. Prior environmental contamination increases the risk of vancomycin-resistant enterococci. Clin Infect Dis 2008, 46:678-685.
22. Zhou Q., Moore C., Eden S., Tong A., McGeer A. Factors associated with acquisition of vancomycin-resistant enterococci (VRE) in roommate contacts of patients colonized or infected with VRE in a tertiary care hospital. Infect Control Hosp Epidemiol 2008, 29:398-403.
23. Carmeli Y., Eliopoulos G.M., Samore M.H. Antecedent treatment with different antibiotic agents as a risk factor for vancomcyin-resistant Enterococcus. Emerg Infect Dis 2002, 8:802-807.
24. Hayakawa K., Marchaim D., Palla M., et al. Epidemiology of vancomycin-resistant Enterococcus faecalis: a case-control study. Antimicrob Agents Chemother 2013, 57:49-55.
25. Rice L.B., Hutton-Thomas R., Lakitcova V., Helfand M.S., Donskey C.J. Β-lactam antibiotics and gastrointestinal colonization with vancomycin-resistant enterococci. JInfect Dis 2004, 189:1113-1118.
26. Paterson D.L., Stiefel U., Donskey C.J. Effect of selective decontamination of the digestive tract regimen including parenteral cefepime on establishment of intestinal colonization and vancomycin-resistant Enterococcus spp. and Klebsiella pneumoniae in mice. Antimicrob Agents Chemother 2006, 50:2537-2540.
27. Stiefel U., Paterson D.L., Pultz N.J., Gordon S.M., Aron D.C., Donskey C.J. Effect of the increasing use of piperacillin-tazobactam on the incidence of vancomycin-resistant enterococci in four academic medical centres. Infect Control Hosp Epidemiol 2004, 25:380-383.
28. Paterson D.L., Muto C.A., Ndirangu M., et al. Acquisition of rectal colonisation by vancomycin-resistant Enterococcus among intensive care unit patients treated with piperacillin-tazobactam versus those receiving cefepime-containing antibiotic regimens. Antimicrob Agents Chemother 2008, 52:465-469.
29. Huang S.S., Rifas-Shiman S.L., Pottinger J.M., et al. Improving the assessment of vancomycin-resistant enterococci by routine screening. JInfect Dis 2007, 195:339-346.
30. Hendrix C.W., Hammond J.M.J., Swoboda S.M., et al. Surveillance strategies and impact of vancomycin-resistant enterococcal colonisation and infection in critically ill patients. Ann Surg 2001, 233:259-265.
31. Price C.S., Paule S., Noskin G.A., Peterson L.R. Active surveillance reduces the incidence of vancomycin-resistant enterococcal bacteremia. Clin Infect Dis 2003, 37:921-928.
32. Hackem R., Graviss L., Hanna H., et al. Impact of surveillance for vancomycin-resistant enterococci on controlling a bloodstream outbreak among patients with haematologic malignancy. Infect Control Hosp Epidemiol 2004, 25:391-394.
33. Milstone A.M., Maragakis L.I., Carroll K.C., Perl T.M. Targeted surveillance to identify children colonised with vancomycin-resistant Enterococcus in the paediatric intensive care unit. Infect Control Hosp Epidemiol 2010, 31:95-98.
34. Singh N., Léger M.-M., Campbell J., Short B., Campos J.M. Control of vancomycin-resistant enterococci in the neonatal intensive care unit. Infect Control Hosp Epidemiol 2005, 26:646-649.
35. Perencevich E.N., Fisman D.N., Lipsitch M., Harris A.D., Morris Lr J.G., Smith D.L. Projected benefits of active surveillance for vancomycin-resistant enterococci in intensive care units. Clin Infect Dis 2004, 38:1108-1115.
36. Matushima A., Takakura S., Yamamoto M., et al. Regional spread and control of vancomycin-resistant Enterococcus faecium and Enterococcus faecalis in Kyoto, Japan. Eur J Clin Microbiol Infect Dis 2012, 31:1095-1100.
37. Lee T.A., Hacek D., Stroupe K.T., Collins S.M., Peterson L.R. Three surveillance strategies for vancomycin-resistant enterococci in hospitalised patients: detection of colonisation efficiency and a cost-effectiveness model. Infect Control Hosp Epidemiol 2005, 26:39-46.
38. Hacek D.M., Bednarz P., Noskin G.A., Zembower T., Peterson L.R. Yield of vancomycin-resistant enterococci and multidrug-resistant Enterobacteriaceae from stools submitted for Clostridium difficile testing compared to results from a focused surveillance program. JClin Microbiol 2001, 39:1152-1154.
39. Leber A.L., Hindler J.F., Kata E.O., Bruckner D.A., Pegues D.A. Laboratory-based surveillance for vancomycin-resistant enterococci: utility of screening stool specimens submitted for Clostridium difficile toxin assay. Infect Control Hosp Epidemiol 2001, 22:160-164.
40. Derde L.P.G., Dautzenberg M.J.D., Bonten M.J.M. Chlorhexidine body washing to control antimicrobial-resistant bacteria in intensive care units: a systematic review. Intensive Care Med 2012, 38:931-939.
41. Huang S.S., Septimus E., Kleinman K., et al. Targeted versus universal decolonisation to prevent ICU infection. New Engl J Med 2013, 368:2255-2265.
42. De Angelis G., Cataldo M.A., De Waure C., et al. Infection control and prevention measures to reduce the spread of vancomycin-resistant enterococci in hospitalized patients: a systematic review and meta-analysis. JAntimicrob Chemother 2014, 69:1185-1192.
43. Huskins W.C., Huckabee C.M., O'Grady N.P., et al. Intervention to reduce transmission of resistant bacteria in intensive care. NEngl J Med 2011, 364:1407-1418.
44. Derde L.P.G., Cooper B.S., Goossens H., et al. Interventions to reduce colonisation and transmission of antimicrobial-resistant bacteria in intensive care units: an interrupted time series study and cluster randomised trial. Lancet Infect Dis 2014, 14:31-39.
45. Brown D.F., Walpole E. Evaluation of selective and enrichment media for isolation of glycopeptide-resistant enterococci from faecal specimens. JAntimicrobial Chemother 2003, 51:289-296.
46. Stamper P.D., Shulder S., Bekalo P., et al. Evaluation of BBL CHROMagar VanRE for detection of vancomycin-resistant enterococci in rectal swab specimens. JClin Microbiol 2010, 48:4294-4297.
47. Hegstad K., Giske C.G., Haldorsen B., et al. Performance of the EUCAST disk diffusion method, the CLSI agar screen method, and the Vitex 2 automated antimicrobial susceptibility testing system for detection of clinical isolates of enterococci with low- and medium-level vanB-type vancomycin resistance: a multicentre study. JClin Microbiol 2014, 52:1582-1589.
48. Wijesuriya T.M., Perry P., Pryce T., et al. Low vancomycin MICs and fecal densities reduce the sensitivity of screening methods for vancomycin resistance in enterococci. JClin Microbiol 2014, 52:2829-2833.
49. Mak A., Miller M.A., Chong G., Momczak Y. Comparison of PCR and culture for screening of vancomycin-resistant enterococci: highly disparate results for vanA and vanB. JClin Microbiol 2009, 47:4136-4137.
50. Ballard S.A., Grabsch E.A., Johnson P.D.R., Grayson M.L. Comparison of three PCR primer sets for identification of vanB gene carriage in faces and correlation with carriage of vancomycin-resistant enterococci: interference by vanB-containing anaerobic bacilli. Antimicrob Ag Chemother 2005, 49:77-81.
51. Usacheva E.A., Ginocchio C.C., Morgan M., et al. Prospective, multicenter evaluation of the BD GeneOhm VanR assay for direct, rapid detection of vancomycin-resistant Enterococcus species in perianal and rectal specimens. Am J Clin Path 2010, 134:219-226.
52. Gazin M., Lammens C., Goossens H. Evaluation of GeneOhm VanR and Xpert vanA/vanB molecular assays for the rapid detection of vancomycin-resistant enterococci. Eur J Clin Microbiol Infect Dis 2012, 31:273-276.
53. Morgan D.J., Day H.R., Furuno J.P., et al. Improving efficiency in active surveillance for methicillin-resistant Staphylococcus aureus or vancomycin-resistant Enterococcus at hospital admission. Infect Control Hosp Epidemiol 2010, 31:1230-1235.
54. Shadel B.N., Puzniak L.A., Gillespie K.N., Lawrence S.J., Kollef M., Mundy L.M. Surveillance for vancomycin-resistant enterococci: type, rates, costs and implications. Infect Control Hosp Epidemiol 2006, 27:1068-1075.
55. Muto C.A., Giannetta E.T., Durbin L.J., Simonton B.M., Farr B.M. Cost-effectiveness of perirectal surveillance cultures for controlling vancomycin-resistant enterococci. Infect Control Hosp Epidemiol 2002, 23:429-435.
56. Montecalvo M.A., Jarvis W.R., Uman J., et al. Costs and savings associated with infection control measures that reduced transmission of vancomycin-resistant enterococci in an endemic setting. Infect Control Hosp Epidemiol 2001, 22:437-442.
57. Fang H., Ohlsson A.K., Jiang G.-X., Ulberg M. Screening for vancomycin-resistant enterococci: an efficient and economical laboratory-developed test. Eur J Clin Infect Dis 2012, 31:261-265.